Form 4: Karyopharm Therapeutics SVP Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, sold 3,971 shares of common stock to cover withholding tax liability.
Summary
- On September 4, 2024, Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics Inc., sold 3,971 shares of common stock.
- The sale was executed at a price of $0.7218 per share.
- The transaction was conducted under a pre-arranged automatic sale plan adopted on May 16, 2022, to cover withholding tax obligations related to the vesting of restricted stock units.
- Following the transaction, Mano directly owns 273,881 shares of Karyopharm Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (sale of shares for tax purposes) by an insider, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This particular filing indicates a sale of shares to cover tax obligations, which is a common practice.
Stakeholder Impact
- The sale of shares by an insider could have a marginal negative impact on shareholder sentiment, although the reason for the sale (tax obligations) is a common and understandable one.
Key Dates
| Date | Description |
|---|---|
| May 16, 2022 | Date of adoption of the durable automatic sale instruction plan. |
| September 4, 2024 | Date of the stock sale transaction. |
| September 5, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.